- REAGENT SERVICES Hot!
-
PRODUCTS
-
Most Popular Reagents
-
Instruments
-
Antibodies
-
ELISA Kits
-
Protein Electrophoresis and Blotting
-
Protein and Antibody Purification
-
Recombinant Proteins
-
Molecular Biology
-
Stable Cell Lines
-
Cell Isolation and Activation
-
IVD Raw Materials
-
Therapy Applications
-
Resources
-
![AmMag™ Quatro Automated Plasmid Purification]()
AmMag™ Quatro automated plasmid purification
-
![Anti-Camelid VHH]()
MonoRab™ Anti-VHH Antibodies
-
![ELISA Kits]()
ELISA Kits
-
![Precast Gels]()
SurePAGE™ Precast Gels
-
![Quatro ProAb Automated Protein and Antibody Purification System]()
AmMag™ Quatro ProAb Automated Protein and Antibody Purification System
-
![Target Proteins]()
Target Proteins
-
![AmMag™ Quatro Automated Plasmid Purification]()
AmMag™ Quatro automated plasmid purification
-
![Stable Cell Lines]()
Stable Cell Lines
-
![Cell Isolation and Activation]()
Cell Isolation and Activation
-
![Quick
Order]()
Quick Order
-
![Quick
Order]()
Quick Order
- APPLICATIONS
- RESOURCES
- ABOUT US
![Cell Isolation and Activation]( "Cell Isolation and Activation")
As a pioneer in the CGT field, GenScript has developed the CytoSinct™ cell isolation platform and Enceed™ T Cell Activation reagents, leveraging its extensive experience in antibody and magnetic bead development, along with its comprehensive expertise in the CGT industry chain. We provide high-quality cell isolation magnetic nanobeads, activation reagents, consumables and instruments to accelerate the R&D and commercialization of cell therapy. All Products >>
Highlighted Products
CytoSinct™ Nanobeads
High-purity target cell isolation with stable, efficient performance and biodegradability
>>View details
Enceed™ T cell Activation Reagents
Efficient T cell activation and expansion, enhanced memorial phenotype, no de-beading step.
>>View details
CytoSinct™ Column and Magnetic Stand
Manual cell separation for reliable, efficient performance
>>View details
CytoSinct™ 1000 Cell Isolation Instrument
Closed, sterile system for targeted enrichment or depletion
>>View details
GMP Grade Cell Isolation and Activation Reagents
Cost-effective Nanobeads and reagents with superior performance, short lead times, stable supply and FDA and EMA compliance
>>View details
Selected Filters
{{productcls1}}{{ itemName }}
Filters-
{{ category.name }}
{{ subCategory.name }}
{{ item.name }}
ResetConfirmNo Data
Selected Citations
- 1. The Gao, Jie, et al. "Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China." The Lancet (2025).
- 2. Markelov, Vladislav, et al. "Scalable and ultrafast CAR-T cell production using microfluidics." Lab on a Chip 25.12 (2025): 3005-3015
- 3. Yang, Chen, et al. "A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity." Cell Reports Medicine 6.10 (2025).
- 4. Hui, Xinhui, et al. "GPR132 regulates the function of NK cells through the Gαs/CSK/ZAP70/NF-κB signaling pathway as a potential immune checkpoint." Science Advances 11.10 (2025): eadr9395.
- 5. Chen, Zhaozhao, et al. "mRNA‐laden lipid nanoparticle‐enabled humanized CD19 CAR‐T‐cell engineering for the eradication of leukaemic cells." British Journal of Haematology 206.2 (2025): 628-643.
- 6. Stepanyan, Nara G., et al. "NK-cell therapy after allogeneic hematopoietic stem cell transplantation in patients with acute leukemias." Cellular Therapy and Transplantation 13.4 (2024): 31-36
- 7. Nenashëva, Tatyana Anatol’yevna, et al. “Comparison of the functional and immunophenotypic profile of anti-CD19-modified T-cells expressing a chimeric antigen receptor, derived from healthy donors and patients with B-cell acute lymphoblastic leukemia, during prolonged in vitro restimulation.” Hematology and Transfusiology 2 (70) (2025): 156-164.
- 8. Chen, Min, et al. "Identification of ENTPD1 as a novel biomarker linking allergic rhinitis and systemic lupus erythematosus." Scientific Reports 14.1 (2024): 18266.
- 9. Hui, Xinhui, et al. "A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma." Frontiers in Immunology 15 (2024): 1462076.
- 10. Xiong, Ying, et al. "Technological and manufacturing innovation drive improved access to engineered T cell therapies." Medical Research Archives 11.11 (2023).
Customer Testimonials
Enceed™ and CytoSinct™ User
Research Staff, Top U.S. Medical Center"GenScript Enceed T cell Activation Reagent and CytoSinct Cell Isolation products have been invaluable for our on-going immune-oncology research."
Resources
Cell Isolation and Activation Flyer
Free Download
Advanced Products for Cell Therapy Overview- Application Note
Free Download
Enceed™ T Cell Activation Reagent
Free Download
Unlock Cell Therapy Potential with Customizable Cell Isolation and Enhanced T cell Activation Solution
Watch Now
Robotic Automation of Cell Isolation with CytoSinct™ 1000 to Streamline Cell Therapy Manufacturing
Watch NowOnline Request Submission
For more information, or to request a demonstration, please submit the form or email us at [email protected]
Nanobeads Customization Request
For more information, or to request a demonstration, please submit the form or email us at [email protected]
-
Show More
Close
